Rubedo reports younger skin age in Phase 1b trial
GPX4-targeting therapy reduces epigenetic age markers and circulating inflammation, raising questions about effects beyond treated skin. Rubedo Life Sciences has reported a statistically significant reduction in measured skin epigenetic age following treatment with its investigational senotherapeuti
<p>GPX4-targeting therapy reduces epigenetic age markers and circulating inflammation, raising questions about effects beyond treated skin. Rubedo Life Sciences has reported a statistically significant reduction in measured skin epigenetic age following treatment with its investigational senotherapeuti</p>